Sublingual immunotherapy: focus on tablets
Annals of Allergy, Asthma & Immunology
July 2015 Volume 115, Issue 1, Pages 4-9 MOC-CME Review
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.
Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Planning Committee Members
Giovanni Passalacqua, MD (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)
Physicians involved in providing patient care in the field of allergy/asthma/immunology
At the conclusion of this activity, participants should be able to:
Recognize the clinical value of tablets for sublingual immunotherapy (SLIT)
Identify indications and contraindications for SLIT with tablets currently approved in the U.S
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance
- 1.00 MOC